Daniil Vitalievich Luppov

Mr. Daniil Vitalievich Luppov

BostonGene Inc
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 November 2021 in Biology Direct
Verified
Journal Article
Open access
PDF file
JRJulian Markovich Rozenberg
Julian Markovich Rozenberg
SZSvetlana Zvereva
Svetlana Zvereva
ADAleksandra Dalina
Aleksandra Dalina
IBIgor Blatov
Igor Blatov
IZIlya Zubarev
Ilya Zubarev
Nick BarlevNick Barlev
Nick Barlev
During oncogenesis, cells become unrestrictedly proliferative thereby altering the tissue homeostasis and resulting in subsequent hyperplasia. This process is paralleled by resumption of cell cycle, aberrant DNA repair and blunting the apoptotic program in response to DNA damage. In most human cancers these processes are associated with malfunctioning of tumor suppressor p53. Intriguingly, in some cases two other members of the p53 family of proteins, transcription factors p63 and p73, can compensate for loss of p53. Although both p63 and p73 can bind the same DNA sequences as p53 and their transcriptionally active isoforms are able to regulate the expression of p53-dependent genes, the strongest overlap with p53 functions was detected for p73. Surprisingly, unlike p53, the p73 is rarely lost or mutated in cancers. On the contrary, its inactive isoforms are often overexpressed in cancer. In this review, we discuss several lines of evidence that cancer cells develop various mechanisms to repress p73-mediated cell death. Moreover, p73 isoforms may promote cancer growth by enhancing an anti-oxidative response, the Warburg effect and by repressing senescence. Thus, we speculate that the role of p73 in tumorigenesis can be ambivalent and hence, requires new therapeutic strategies that would specifically repress the oncogenic functions of p73, while keeping its tumor suppressive properties intact.

13 December 2021 in Cells
Verified
Journal Article
Open access
PDF file
JRJulian Markovich Rozenberg
Julian Markovich Rozenberg
SZSvetlana Zvereva
Svetlana Zvereva
ADAlexandra Dalina
Alexandra Dalina
IBIgor Blatov
Igor Blatov
IZIlya Zubarev
Ilya Zubarev
Nick BarlevNick Barlev
Nick Barlev
Understanding the mechanisms that regulate cancer progression is pivotal for the development of new therapies. Although p53 is mutated in half of human cancers, its family member p73 is not. At the same time, isoforms of p73 are often overexpressed in cancers and p73 can overtake many p53 functions to kill abnormal cells. According to the latest studies, while p73 represses epithelial–mesenchymal transition and metastasis, it can also promote tumour growth by modulating crosstalk between cancer and immune cells in the tumor microenvironment, M2 macrophage polarisation, Th2 T-cell differentiation, and angiogenesis. Thus, p73 likely plays a dual role as a tumor suppressor by regulating apoptosis in response to genotoxic stress or as an oncoprotein by promoting the immunosuppressive environment and immune cell differentiation.

3 September 2026 in Nature Methods
Verified
Journal Article
Closed access
PDF file
MSMikhail Shugay
Mikhail Shugay
DLDaniil Vitalievich Luppov
Daniil Vitalievich Luppov
EVElizaveta K. Vlasova
Elizaveta K. Vlasova
DCDmitry M. Chudakov
Dmitry M. Chudakov

17 March 2026 in Cancer Immunology Research
Verified
Journal Article
Closed access
PDF file
ISIrina A. Shagina
Irina A. Shagina
TNTatyana O. Nakonechnaya
Tatyana O. Nakonechnaya
AIAnna Izosimova
Anna Izosimova
ASAlexandra V. Shabalkina
Alexandra V. Shabalkina
DYDiana V. Yuzhakova
Diana V. Yuzhakova
GSGeorge Vladimirovich Sharonov
George Vladimirovich Sharonov
In humans and mice, the T-cell receptor (TCR) of each effector/memory T-cell clone recognizes one to several cognate peptide–MHC complexes (pMHC). Limited knowledge of TCR repertoire specificities restricts our capacity to rationally interpret this information, both diagnostically and in preclinical research. In this study, we (i) developed and validated a cost-efficient wet lab and computational pipeline to identify mouse TCRs specific to particular peptides, (ii) produced a dataset of helper T cell (Th) TCR beta chain CDR3s specific to B16 melanoma neoantigens in the I-Ab pMHCII context, available in VDJdb, and (iii) applied this dataset to track tumor-specific T-cell responses to the CTLA4 blocking immunotherapy in the orthotopic B16 melanoma model. We showed that B16-specific TCR motifs expanded in both Th and regulatory T cell (Treg) repertoires of tumor-bearing mice, with stronger expansion in the Th subset of mice treated with the CTLA4 blocking antibody. The response was stochastic across individual mice with respect to the specific TCR motifs and target peptides involved—each mouse displayed a unique response pattern, likely reflecting the natural diversity of molecular pathways underlying antitumor immunity. We also showed that CTLA4 blockade promotes prominent Th clonal expansion and induces general, nontumor-specific Th-to-Treg plasticity. Altogether, we provide a universal pipeline for the investigation of mouse T-cell responses at the antigen-specific level, facilitating the development and validation of immunotherapeutic and vaccination approaches.

10 February 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
DLDaniil Vitalievich Luppov
Daniil Vitalievich Luppov
EVElizaveta K. Vlasova
Elizaveta K. Vlasova
DCDmitry M. Chudakov
Dmitry M. Chudakov
MSMikhail Shugay
Mikhail Shugay
Thymic selection is a multi-stage process that establishes a T-cell immunity that is efficient in fighting diverse foreign pathogens, while not being self-reactive. During the process, T-cell receptor (TCR)α and β chains are rearranged to form a highly diverse set of heterodimers that are selected based on their affinity to peptides presented by major histocompatibility molecules (MHC) in the thymus. Here we employ high-throughput TCR sequencing data, theoretical model of TCR rearrangement and dedicated statistical methods to infer how the selection process affects human TCR repertoire on different scales. On a global scale, our results indicate differences in V(D)J gene usage, complementarity determining region 3 (CDR3) amino acid composition, CDR3 physicochemical properties, k-mer composition and differences in loop structure induced by the selection process. On a local scale, we were able to determine enriched TCR motifs and “holes” in repertoire induced by positive and negative selection and characterize their features. Finally, we demonstrated how TCR sequence composition affects lineage commitment via thymic selection and highlighted the effect of individual MHC haplotype. Our results can aid in identification of potentially self-reactive TCRs in donor repertoires in autoimmunity and immunotherapy studies. Graphical abstract (Figure 0): Study overview. A. Datasets used in the study and the way TCR sequences were analyzed. B. Main directions in which thymic selection shapes TCR repertoire. Selection results in TCR-CDR3 losing positively charged and large amino-acids while increasing its flexibility. Unlike CDR3 of the TCRα chain, CDR3β hydrophobicity is also increased by selection. CDR3s carrying Cysteines and glycosylation sites are unlikely to pass the selection. In contrast, CDR3 carrying poly-Glycine regions are more likely to be selected for both chains. T-cells committed to CD8+ lineage were more likely to feature bulged CDR3s compared to CD4+. C. CDR3s enriched after thymic selection guide lineage commitment according to single-cell RNA sequencing data analysis, e.g. the MAIT cells and CD8+ phenotypes. D. Enrichment and depletion of certain TCR motifs pinpoint fine-structure of post-selection repertoires, as inferred by sequence neighborhood analysis. E. Comparative analysis of enriched and depleted TCR clusters in monozygotic twins revealed that the selection process is shaped by HLA haplotype.

23 September 2026 in Nucleic Acids Research
Verified
Journal Article
Open access
DLDaniil Vitalievich Luppov
Daniil Vitalievich Luppov
AKAnna E Koneva
Anna E Koneva
DBDmitry Bagaev
Dmitry Bagaev
AAAnastasiia V Alexandrova
Anastasiia V Alexandrova
EVElizaveta K Vlasova
Elizaveta K Vlasova
MSMikhail Shugay
Mikhail Shugay
We present a significant update to VDJdb, introducing substantial enhancements to both the data content and the technical infrastructure. The integration of steadily accumulating T-cell receptor (TCR):epitope recognition data, together with advances in high-throughput experimental techniques, has expanded the landscape for machine learning-based prediction of TCR specificity, covering foreign antigens, neoantigens, and autoimmunity-associated epitopes. However, these advances have introduced new challenges, most notably in data quality—large-scale assays have heightened concerns about measurement reliability and exacerbated existing issues such as HLA and epitope coverage biases. To address these issues, we have adopted state-of-the-art artificial intelligence approaches, including protein sequence embeddings and AI-driven structure prediction. The updated VDJdb resource now features TCR specificity records annotated with embedding-derived paratope features, advanced noise filtering capabilities, and predicted three-dimensional protein structures. These improvements enable more comprehensive interrogation of TCR–epitope recognition and provide novel lines of evidence to support the reliability of high-throughput assay records, which are frequently limited by insufficient independent validation. VDJdb can be accessed at https://vdjdb.com and https://github.com/antigenomics/vdjdb-db.